2023
1356-P: Association of HbA1c with Diabetes Outcomes across Health Status Categories in Older Adults
LIPSKA K, HUANG E, LIU J, PARKER M, MOFFET H, GRANT R, LAITEERAPONG N, KARTER A. 1356-P: Association of HbA1c with Diabetes Outcomes across Health Status Categories in Older Adults. Diabetes 2023, 72 DOI: 10.2337/db23-1356-p.Peer-Reviewed Original ResearchComplication riskPoor healthIntermediate healthOlder adultsGood healthIntegrated healthcare delivery systemAssociation of HbA1cType 2 diabetesProportional hazards modelNational InstituteHealth status categoriesHealthcare delivery systemEligible patientsMacrovascular eventsSevere hypoglycemiaKidney diseaseClinical variablesDiabetes outcomesEndocrine SocietyAbbVie Inc.Hazards modelComplicationsHealth statusTwin healthPatients719-P: Feasibility and Acceptability of the Quality of Life, Burden of Treatment, Safety, and Avoidance of Future Events Agenda Setting Kit (QBSAFE ASK)
HAIDER S, GONZALEZ LOPEZ C, CLARK J, GRAVHOLT D, BRESLIN M, BOEHMER K, HARTASANCHEZ S, SANCHEZ B, MONTORI V, LIPSKA K. 719-P: Feasibility and Acceptability of the Quality of Life, Burden of Treatment, Safety, and Avoidance of Future Events Agenda Setting Kit (QBSAFE ASK). Diabetes 2023, 72 DOI: 10.2337/db23-719-p.Peer-Reviewed Original ResearchSingle-arm intervention studyStudy proceduresRoutine clinic visitsBurden of treatmentDiabetes-related topicsQuality of lifeClinic visitsMost patientsDiabetes carePatient goalsClinical careClinician responsesPatientsParticipant enrollmentIntervention studiesCliniciansAcceptability surveyCommon beingNational InstituteConversation CardsCareTreatmentEnrollmentAcceptabilityDiabetes
2019
1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy
MCCOY R, LIPSKA K, HOUTEN H, SHAH N. 1249-P: Development and Validation of a Measure for Appropriateness of Glucose-Lowering Therapy. Diabetes 2019, 68 DOI: 10.2337/db19-1249-p.Peer-Reviewed Original ResearchGlucose lowering therapiesOptimal therapeutic regimensGlucose lowering medicationsDiabetes quality indicatorsNational InstituteMedicare Advantage enrolleesPatient-centered approachHigh-complexity patientsPerson/yearComorbidity burdenHospitalization visitsTreatment burdenHypoglycemia riskKidney diseaseTherapeutic regimensNational cohortNumber/typeClinical complexityPatientsMedicaid ServicesOptumLabsDiabetesTherapyVisitsAmerican Association1607-P: Prevalence and Correlates of Potential Glycemic Overtreatment and Undertreatment among U.S. Adults with Diabetes
MCCOY R, LIPSKA K, HOUTEN H, SHAH N. 1607-P: Prevalence and Correlates of Potential Glycemic Overtreatment and Undertreatment among U.S. Adults with Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-1607-p.Peer-Reviewed Original ResearchType 1 diabetesClinical complexityRace/ethnicityMale sexYounger ageAsian race/ethnicityHispanic race/ethnicityGlucose-lowering medicationsPoor glycemic controlLong-term complicationsHigh clinical complexityNational InstituteMedicare Advantage enrolleesAdministrative claims datasetEndocrine managementPatient comorbiditiesGlycemic controlTreatment regimenStudy cohortKidney diseasePotential overtreatmentDiabetesFM managementOvertreatmentU.S. adults379-P: Changes in Diabetes Management after a Hospital Visit for Severe Hypoglycemia
VIJAYAKUMAR P, LIU S, KAHN P, MCCOY R, KARTER A, LIPSKA K. 379-P: Changes in Diabetes Management after a Hospital Visit for Severe Hypoglycemia. Diabetes 2019, 68 DOI: 10.2337/db19-379-p.Peer-Reviewed Original ResearchSevere hypoglycemic eventsType 2 diabetesDiabetes managementSevere hypoglycemiaHypoglycemic eventsNational InstituteGlucose-lowering medicationsGlucose-lowering therapyProportion of patientsThird of patientsEmergency department visitsPhysician office visitsContinuous glucose monitor useBaseline HbA1cED visitsDepartment visitsHospital admissionKidney diseaseOffice visitsMean ageHospital visitsClinical guidelinesMedication fillsHypoglycemiaDiabetes
2018
Cost-Related Insulin Underuse Is Common and Associated with Poor Glycemic Control
HERKERT D, VIJAYAKUMAR P, LUO J, SCHWARTZ J, RABIN T, DEFILIPPO E, LIPSKA K. Cost-Related Insulin Underuse Is Common and Associated with Poor Glycemic Control. Diabetes 2018, 67 DOI: 10.2337/db18-2-or.Peer-Reviewed Original ResearchCost-related underusePoor glycemic controlGlycemic controlDiabetes CenterCross-sectional surveyDM durationPrimary outcomeLess insulinHigher oddsPatientsSmall dosesDrug coverageLogistic regressionInsulinUnderuseMedicaid ServicesEssential medicinesNational InstituteInsulin 3Lower income levelsInsulin 5AgePositive responseHealthUrgent need